The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes
- Conditions
- Infertility
- Interventions
- Registration Number
- NCT02114645
- Lead Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
- Brief Summary
This prospective clinical trial evaluates the effect of a two dose GnRH agonist administered in the luteal phase on the outcome of ART cycles stimulated with the long GnRH agonist and GnRH antagonist protocol.
- Detailed Description
This prospective clinical trial evaluates the effect of a two dose GnRH agonist administered in the luteal phase on the outcome of ART cycles stimulated with the long GnRH agonist and GnRH antagonist protocol. Decision between each of these two protocols was subjective and depended on the clinical context.In addition to routine luteal phase support with progesterone and estradiol valerate,women received two dose of GnRH agonist on the fifth and tenth day after ET.Live birth rate was the primary outcome measure.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 100
- Couples undergoing ART with their own gametes.
- Couples having at least one good embryo available for transfer.
- Normoresponder
- Infertility etiology is unexplained
- ovulation triggered by intramuscular injection of 10000 IU of HCG
Patients older than 38 years old
- High and poor responder patients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description LongGnRH agonist protocol(controlgroup) vaginal progesterone Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate Long protocol-leuprolide acetate Leuprolide acetate Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer Long protocol-leuprolide acetate vaginal progesterone Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer GnRHantagonist protocol(control group) vaginal progesterone GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate antagonist protocol-leuprolide acetate vaginal progesterone GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer antagonist protocol-leuprolide acetate Leuprolide acetate GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer LongGnRH agonist protocol(controlgroup) 4 mg oral estradiol valerate Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate Long protocol-leuprolide acetate 4 mg oral estradiol valerate Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer GnRHantagonist protocol(control group) 4 mg oral estradiol valerate GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate antagonist protocol-leuprolide acetate 4 mg oral estradiol valerate GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
- Primary Outcome Measures
Name Time Method Live Birth Rate 42 weeks
- Secondary Outcome Measures
Name Time Method Ongoing pregnancy more than 20 weeks miscarriage up to 20 weeks OHSS up to 10 weeks
Trial Locations
- Locations (1)
Zekai Tahir Burak Hospital
🇹🇷Ankara, Cankaya, Turkey